New data about ARASENS trial: it seems to work well after longer observation

[Maxone73]

Post-Hoc Analysis of ARASENS Reinforces Use of Darolutamide/ADT/Docetaxel Combo as SOC in mHSPC

onclive.com/view/post-hoc-a...

[KocoPr]

excellent for newly diagnosed and HSPC. I wonder if would be similar for ongoing daro and ADT and still hormone sensitive?

I won’t try chemo yet as I am thoroughly enjoying pBAT.

[Maxone73 in reply to KocoPr]

hopefully good news for me...as I am on Arasens

[KocoPr in reply to Maxone73]

I did not know you were on that trial.

So you’re taking daro with your triplet therapy?

It’s a very good ARi

[Maxone73 in reply to KocoPr]

I finished with the chemo 18 days ago, now carrying on with daro + adt

[Purple-Bike in reply to KocoPr]

Yes, it appears ARASENS is valid for the recurrent as well as de novo mHSPC:

"In ARASENS, the treatment effect of darolutamide on OS was favourable in patients with de novo (HR 0.71; 95% CI 0.59 to 0.85) and recurrent (HR 0.61; 95% CI 0.35 to 1.05) metastatic hormone-sensitive prostate cancer" .

From esmo.org/oncology-news/daro...

I wonder if a case can be made for just daro+ADT for the recurrent?

[Maxone73 in reply to Purple-Bike]

that is called ARASTEP I think, but I am not sure if there are preliminary results available